Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of bimekizumab for psoriasis involving high-impact sites
ChiCTR2600135299Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimekizumab in plaque psoriasis and psoriasis, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: 16-week PASI 90 response rate, 16-week PASI 100 response rate and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on ChiCTR2600135299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135299.